FDA approves Eysuvis (loteprednol etabonate) ophthalmic suspension 0.25% for short-term treatment of dry eye disease

Approval of this glucocorticoid agonist was based on results of four clinical trials, across which statistical significance was achieved after two weeks of treatment for conjunctival hyperemia and ocular discomfort severity. UK developmental status is unknown.

Source:

Biospace Inc.